Lv1
30 积分 2025-01-14 加入
Acquired resistance mechanisms to osimertinib: The constant battle
18天前
已完结
Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy
24天前
已完结
Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors
24天前
已完结
CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy
2个月前
已完结
PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?
2个月前
已完结
Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal
4个月前
已完结
The LSD1/HDAC dual-target inhibitor for cancer therapy: Challenge and opportunity
4个月前
已完结
Leveraging non-enzymatic functions of LSD1 for novel therapeutics
5个月前
已完结
皖公网安备34019202002308
